Showing 711-720 of 797 results for "".
- Diet High in Fish and Vegetables May Help Preserve Cognitionhttps://practicalneurology.com/news/diet-high-in-fish-and-vegetables-may-help-preserve-cognition/2469228/Results of a study published in Alzheimer (AD) and Dementia show adherence to the Mediterranean diet (high in vegetables, whole grains, fish, and olive oil) correlates with higher cognitive function. Dietary factors also seem to play a role in slowing cognitive decline. Researchers at the Nationa
- Imaavy Outperforms Other FcRn Blockers in Sustained gMG Symptom Controlhttps://practicalneurology.com/news/imaavy-outperforms-other-fcrn-blockers-in-sustained-gmg-symptom-control/2475453/Results of an indirect treatment comparison (ITC) demonstrated that Imaavy (nipocalimab-aahu; Johnson & Johnson, New Brunswick, NJ) treatment was associated with consistent and sustained improvement in generalized myasthenia gravis (gMG) symptoms in individuals aged ≥12 years with anti-acetyl
- Antibody–Oligonucleotide Conjugate Shows Target Engagement in Myotonic Dystrophy Type 1https://practicalneurology.com/news/antibodyoligonucleotide-conjugate-shows-target-engagement-in-myotonic-dystrophy-type/2485921/Treatment with delpacibart etedesiran (del-desiran [AOC 1001]; Avidity Biosciences, San Diego, CA), a monoclonal antibody (mAb) oligonucleotide conjugate, reduced DMPK mRNA levels and demonstrated improvement in downstream splicing biomarkers in adults with myotonic dystrophy type 1 (DM1). These
- FDA Grants Breakthrough Therapy Designation to Delpacibart Zotadirsen for Duchenne Muscular Dystrophyhttps://practicalneurology.com/news/fda-grants-breakthrough-therapy-designation-to-delpacibart-zotadirsen-for-duchenne-muscular-dystrophy/2475932/Del-zota (delpacibart zotadirsen; Avidity Biosciences, San Diego, CA) has been granted Breakthrough Therapy designation by the Food and Drug Administration (FDA) as an investigational therapy for the treatment of people with Duchenne muscular dystrophy (DMD) with mutations amenable to exon 44 ski
- Draft Guidelines for the Treatment of Infantile Epilepsy Syndromes: Comments Requestedhttps://practicalneurology.com/news/new-guidelines-proposed-for-treatment-of-infantile-epilepsy-syndromes-comments-requested/2475300/The American Epilepsy Society (AES) has released a comprehensive draft clinical practice guideline that provides evidence-based recommendations for the pharmacologic, surgical, and dietary treatment of epilepsy syndromes in infants aged <36 months. The guideline updates a previously published
- Ingrezza Treatment for Older Adults with Tardive Dyskinesia Safe and Effective Long-Term According to New Studyhttps://practicalneurology.com/news/ingrezza-treatment-for-older-adults-with-tardive-dyskinesia-demonstrates-long-term-safety-and-efficacy/2474394/According to results of a post hoc analysis of the KINECT-3 (NCT02274558) and KINECT-4 (NCT02405091) clinical studies published in the Journal of Clinical Psychiatry, older adults with tardive dyskinesia (TD) treated with once-daily Ingrezza (valbenazine; Neurocrine Biosciences, San Dieg
- Ingrezza Treatment for Tardive Dyskinesia Improved Functional, Social, Emotional, and Health-Related Quality of Life Measureshttps://practicalneurology.com/news/ingrezza-treatment-for-tardive-dyskinesia-improved-functional-social-emotional-and-health-related-quality-of-life-measures/2470633/Treatment with Ingrezza (valbenazine; Neurocrine Biosciences, San Diego, CA) was associated with improvements in functional, social, emotional, and health-related quality of life measures for people with tardive dyskinesia (TD). The findings of 3 separate analyses of clinical study and survey dat
- Nuplazid Safety and Efficacy As Treatment for Neuropsychiatric Symptoms in Frail Older Adults with Neurodegenerative Disease Reportedhttps://practicalneurology.com/news/nuplazid-safety-and-efficacy-as-treatment-for-neuropsychiatric-symptoms-in-frail-older-adults-with-neurodegenerative-disease-reported/2470606/Results from a 52-week, multicenter, phase 3b, open-label extension study (NCT03623321) revealed that Nuplazid (pimavanserin; Acadia Pharmaceuticals, San Diego, CA) was effective and generally safe as a treatment for neuropsychiatric symptoms in frail older adults with neurodegenerative
- New FDA-Cleared Software Update Enhances MRI Analysis for ARIA Detectionhttps://practicalneurology.com/news/new-fda-cleared-software-update-enhances-mri-analysis-for-aria-detection/2470568/NeuroQuant v5.0 (Cortechs.ai, San Diego, CA), the latest update to NeuroQuant (Cortechs.ai, San Diego, CA) neuroimaging analysis software, has received Food and Drug Administration (FDA) 510(k) clearance. The update enables the identification and evaluation of focal brain lesions in MRI images, w
- Investigational Therapy for Facioscapulohumeral Muscular Dystrophy Shows Promise According to Avidity Bioscienceshttps://practicalneurology.com/news/investigational-therapy-for-facioscapulohumeral-muscular-dystrophy-shows-promise-according-to-avidity-biosciences/2470511/Initial 4-month results from the phase 1/2 FORTITUDE clinical trial (NCT05747924) reveal that treatment of people with facioscapulohumeral muscular dystrophy (FSHD) using AOC 1020 (delpacibart braxlosiran [del-brax]; Avidity Biosciences, San Diego, CA) is associated with functional improvement an